MedTrace Logo

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

NCT00245739 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2014-04-11

No results posted yet for this study

Summary

The purpose of this study is to provide early access to TMC114 (a protease inhibitor) for HIV-1 infected patients with limited or no treatment options, who have failed multiple antiretroviral (ARV) regimens, and to evaluate the longer-term safety and tolerability of TMC114/r in combination with other antiretrovirals

Conditions

  • HIV Infections

Interventions

DRUG

TMC-114

600/100 mg tablets of TMC114/rtv BID until commercial available to the subject

Sponsors & Collaborators

  • Tibotec Pharmaceuticals, Ireland

    lead INDUSTRY

Principal Investigators

  • Tibotec Pharmaceuticals Clinical Trial · Tibotec Pharmaceutical Limited

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • Denmark
  • Germany
  • Greece
  • Hungary
  • Luxembourg
  • Malaysia
  • Mexico
  • Netherlands
  • Puerto Rico
  • Russia
  • Slovenia
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • Venezuela

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245739 on ClinicalTrials.gov